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Background and aims: The aim of this study was to develop an integrated central blood pressure–aortic stiffness
(ICPS) risk score to predict cardiovascular events. Methods: It was a retrospective cohort study. A total of 100
chronic kidney disease (CKD) patients on conservative therapy were included. Pulse wave velocity (PWV), central
systolic blood pressure (cSBP), and central pulse pressure (cPP) were measured. A score was assigned to tertiles of
PWV (0–2), cPP (0–2), and cSBP (0 to the first and second and 1 to the third tertile) based on each parameter’s ability
to individually predict cardiovascular outcome. The sum of these scores and three ICPS risk categories as predictors
were studied. Finally, we compared discrimination of the ICPS risk categories with PWV, cSBP, and cPP. Results:
Adjusted for age and sex, patients in high and very high ICPS risk categories had increased cardiovascular risk
(HR: 3.52, 95% CI: 1.65–7.49; HR: 7.56, 95% CI: 3.20–17.85, respectively). High and very high ICPS risk
categories remained independent predictors in a model adjusted for multiple CV risk factors (HR: 4.58, 95%
CI: 1.65–7.49; HR: 8.56, 95% CI: 3.09–23.76, respectively). ICPS risk categories (Harrell’s C: 0.723, 95% CI:
0.652–0.795) showed better discrimination than PWV (Harrell’s C: 0.659, 95% CI: 0.586–0.732, p= 0.028) and
cSBP (Harrell’s C: 0.660, 95% CI: 0.584–0.735, p= 0.008) and there has been a tendency of significance in case of
cPP (Harrell’s C: 0.691, 95% CI: 0.621–0.761, p= 0.170). Conclusion: The ICPS score may clinically importantly
improve the identification of CKD patients with elevated cardiovascular risk.
Keywords: chronic kidney disease, central blood pressure, central pulse pressure, pulse wave velocity,
cardiovascular outcome
Introduction
Given that cardiovascular (CV) diseases are still the leading causes of mortality worldwide
and that an armamentarium of effective preventive medications is available, it is of utmost
importance to accurately predict CV risk in different populations to increase the health
benefits of CV prevention (5). Measurements of arterial stiffness and central hemodynamic
status are contenders that may improve CV risk prediction over and above classical tools.
These parameters have been extensively investigated in the past two decades. In all stages of
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chronic kidney disease (CKD), arterial stiffness is an important risk factor for CV events and
mortality (13).
The most important marker of arterial stiffness is the carotid-femoral pulse wave
velocity (PWV). It was found to be predictive in different patient populations and was
included in European hypertension guidelines since 2007. However, the most recent
European guideline on CV risk prevention advised against its use for CV risk assessment
in the general population (12).
Among parameters describing central hemodynamics, central systolic blood pressure
(cSBP, a measure of pressure load) and central pulse pressure (cPP, describing pulsatility)
seem to be the most promising, as they have better predictive values compared to brachial
systolic and pulse pressure in some conditions (1, 7), although no additional advantage was
found compared to brachial pressure in the Framingham Heart Study (8).
Another measure, the augmentation index (Aix), is a wave reflection parameter that also
describes total peripheral resistance. It has also been reported to be an independent predictor
of CV outcomes (6), but results are conflicting (8, 11).
Although most available literature on arterial stiffness investigates the predictive power
of stiffness parameters individually, given that PWV, cSBP, cPP, and Aix can be obtained
with most available devices at a single measurement, and that they reflect different aspects of
the vasculature, it seems reasonable to combine their results into a single score to predict
vascular events.
Our aims were to investigate the following in CKD patients on conservative therapy:
(1) the predictive power of PWV, cSBP, cPP, and Aix individually for CV events; (2) to
translate these parameters into simple scores based on their tertiles; (3) to establish and test for
CV prediction an integrated parameter as the sum of these scores and based and these scores,
different risk categories; and (4) to test whether the integrated score-based risk category
concept improves CV prediction compared with its components separately.
Methods
It was a retrospective cohort study. Scientific results from this cohort were published previously
(1, 10). Patients were recruited from two tertiary care nephrology outpatient clinics. Conve-
nience sampling was used with the consecutive inclusion of CKD patients. None of the patients
were hospitalized during baseline investigations. CKD patients at stages 1–5, not on dialysis
therapy, who gave written informed consent for participation, were included. Patients with
atrial fibrillation or with frequent ventricular extrasystoles counteracting with pulse wave
analysis were excluded. After baseline clinical, laboratory, arterial stiffness, and central
hemodynamic measurements, patients were followed for a median of 67.6 months (interquartile
range: 38.4–82.6). Follow-up data were collected between April 2007 and July 2014 by yearly
telephone interviews either with the patients, their general practitioners, or treating physicians.
All endpoint information was verified by original chart review. Follow-up was censored at the
last occurrence of a documented CV event (acute coronary syndrome, heart failure requiring
hospitalization, stroke or transient ischemic attack, or peripheral artery disease with the need for
an intervention) or death due to the above CV causes.
The protocol was approved by the local ethical committees of the participating hospitals
and was carried out in accordance with the tenets of the Declaration of Helsinki. All patients
gave written informed consent before participation.
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Arterial stiffness, central hemodynamic, and blood pressure measurements
All measurements were performed between 10 a.m. and 12 p.m. Patients were allowed to take
a non-standardized light breakfast and took their regular medications at least 3 h before the
study measurements. They were asked to refrain from smoking on the day of the study and
not to consume any caffeine-containing drinks at least 4 h before initiating the measurements.
Arterial stiffness measurements and blood sampling were carried out on separate days within
a week.
Arterial stiffness measurements were carried out in a temperature-controlled room
(24± 1 °C). Upon arrival after a 5-min rest, two consecutive brachial blood pressure
measurements were taken 1 min apart on each arm in the sitting position with a validated
BpTru device (VSMMedtech, Vancouver, Canada). The mean value was calculated for each
arm, and the higher of these was further taken as brachial systolic and diastolic blood pressure
and heart rate. Subjects were then set in the supine position for a 10-min acclimatization
period.
Arterial stiffness was measured with the “gold-standard” tonometric method, above
the carotid and femoral sites, using the PulsePen device. We referred our previous
publication for the PWV and cPP measurements (1). Aix was measured by automatic
identification of the “1st shoulder” (inflexion point) on the averaged carotid pulse signal by
the PulsePen software. The pressure amplitude following this point divided by the pulse
pressure provided the Aix. CSBP was directly calculated from the carotid pulse waveform
using the calibration considering brachial systolic and diastolic blood pressures.
Epidemiologic and Laboratory data
Baseline data on current smoking, any type of diabetes mellitus, hypertension, coronary
artery disease (previous acute myocardial infarction or coronary intervention), chronic heart
failure (previous diagnosis), peripheral arterial disease (documented by angiography or
intervention), and cerebrovascular disease (previous stroke or transient ischemic attack) were
collected by health record review.
Blood samples for the determination of blood cell count and hemoglobin, serum
cholesterol, triglyceride, and low-density lipoprotein (LDL)-cholesterol were collected at
baseline. Routine blood chemistry measurements were carried out directly after blood
sampling on a Hitachi auto-analyzer. Baseline estimated glomerular filtration rate was
calculated using the four-variable Chronic Kidney Disease Epidemiology Collaboration
equation.
Statistical analyses
All data analyses were performed using SPSS 23 (SPSS Inc., Chicago, IL, USA) for
Windows (descriptives and Cox regression analyses) or Stata version 13.1 (Harrell’s
C-statistics). Continuous data are given as mean and standard deviation (SD), or in case
of evidence against a normal distribution, as a median and interquartile range.
The primary outcome of the study was the occurrence of the combined endpoint of CV
events and CV mortality, as defined above.
To assess the predictive values of the studied parameters for the primary outcome,
multiple failure times Cox proportional hazard regression analyses were used with condi-
tional risk set modeling. This method accommodates for the fact that one patient may have
had more than one event during follow-up.
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No a priori power calculations were carried out for the current analysis; however, the
sample size for the original study was based on the observed differences and the distribution
of one of the arterial stiffness measures (cPP) (1). A post hoc power calculation showed
power values ranging from 0.60 to 0.97 for individual arterial stiffness parameters (as
continuous variables) for the prediction of CV events.
Arterial stiffness and central hemodynamic parameters were analyzed both as contin-
uous and categorical variables. For the former, these variables were transformed into
z-scores to improve their comparability and thus the associations are given for one SD
differences in PWV, cSBP, cPP, and Aix for the CV outcome. Model 1 was adjusted for
age and sex, Model 2 was further adjusted for brachial systolic blood pressure,
LDL-cholesterol, current smoking, diabetes, body mass index, known CV disease, and
GFR-EPI. As in the cohort, all but one patient had hypertension, we omitted this variable
from the adjustment.
Next, patients were divided into tertiles based on their PWV, cSBP, cPP, and Aix values,
respectively. Survival was investigated using Kaplan–Meier analysis and Cox regressions
similar to the ones described above, with arterial stiffness and central hemodynamic
parameters as predictors and CV events or CV mortality as outcome. Polynomial and simple
contrasts were performed to investigate the best scoring for these tertiles. According to these
results, Aix was not related to CV outcome and was excluded from further analysis. There
was a linear association between PWV and cPP and CV outcomes and accordingly 0, 1, and
2 points were given to the consecutive tertiles. As the risk of CV events or CV mortality only
increased in the third tertile of cSBP, 0 points were given to the first two tertiles and 1 point to
the third.
The integrated central blood pressure–aortic stiffness (ICPS) score was calculated for
each patient by summing the points based on tertiles (range: 0–5 points). Survival was
investigated with Kaplan–Meier and Cox regression analyses (adjusted for age and sex) with
ICPS score as the predictor and CV event or CV mortality as outcome. Given the limited
statistical power of our relatively small sample size, patients were classified into three ICPS
risk categories: average (0–2 points), high (3–4 points), or very high (5 points). The
predictive role of these risk categories were investigated in Kaplan–Meier curves and Cox
regressions with adjustment (1) for age and sex and (2) with further adjustment for brachial
systolic blood pressure, LDL-cholesterol, current smoking, diabetes, body mass index, CV
disease, and GFR-EPI.
Finally, the ICPS risk categories and one SD change of each of its components (PWV,
cSBP, and cPP) were analyzed in the same Cox regression model for CV outcomes.
To investigate model discrimination, Harrell’s concordance statistics were utilized.
As sensitivity analysis, all of the measurements were performed using Cox regression
analyses, considering the occurrence of the first CV event instead of multiple failure time
analysis as well.
Results
Of the 108 patients eligible for inclusion, five individuals declined participation. Further-
more, three patients were excluded because of missing baseline or follow-up data, leaving
100 subjects in the analytical sample.
Table I displays baseline characteristics, including concomitant diseases, traditional and
non-traditional CV risk factors, and metabolic and vascular parameters.
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The causes of kidney disease were heterogeneous (number of cases in parentheses):
glomerulonephritis (n= 14), diabetic nephropathy (n= 29), hypertensive nephrosclerosis
(n= 17), chronic tubulointerstitial nephritis (n= 18), vascular cause (n= 6), polycystic
kidney disease (n= 6), tumor (n= 1), and unknown (n= 9).
All but one patient received antihypertensive medication (case numbers in parentheses):
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (n= 89), calcium
channel blockers (n= 52), diuretics (n= 74), β-receptor blockers (n= 54), α-receptor
Table I. Baseline demographic, clinical, and laboratory characteristics (n= 100)
Male (n) 48
Age (years) 66.00 (58.25–75.00)
BMI (kg/m2) 27.63 (25.24–30.49)
Current smoker 12
Diabetes mellitus 44
Baseline cardiovascular disease 64
Coronary artery disease 13
Chronic heart failure 19
Cerebrovascular disease 24
Peripheral artery disease 53
eGFR (ml/min per 1.73 m2) 35.74 (23.15–49.43)
Hgb (g/L) 126.89 (14.32)
Chol (mmol/L) 4.81 (4.28–5.33)
Tg (mmol/L) 1.80 (1.15–2.60)
LDL (mmol/L) 2.57 (0.84)
SBP (mmHg) 135.50 (120.31–145.44)
DBP (mmHg) 73.12 (9.70)
HR (L/min) 62.25 (57.50–72.63)
PP (mmHg) 60.38 (50.56–70.38)
PWV (m/s) 11.26 (8.90–14.90)
Aix (%) 21.53 (15.35–26.83)
cSBP (mmHg) 124.33 (14.50)
cPP (mmHg) 48.58 (42.75–60.38)
Categorical parameters are presented as n, numbers can be also considered as percentage. Continuous data
are presented as mean (SD) or median (interquartile range). Aix: augmentation index; BMI: body mass index;
Chol: cholesterol; cPP: central pulse pressure; cSBP: central systolic blood pressure; DBP: brachial diastolic blood
pressure; eGFR: estimated glomerular filtration rate; Hgb: hemoglobin; HR: heart rate; LDL: low-density lipoprotein;
n: case number; PP: brachial pulse pressure; PWV: carotid-femoral pulse wave velocity; SBP: brachial systolic blood
pressure; Tg: triglyceride
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blockers (n= 18), long-acting nitrate (n= 15), and centrally acting antihypertensive drugs
(n= 13), either alone or in combination. Low dose aspirin was taken by n= 36 patients,
whereas n= 17 individuals took clopidogrel. Sixty-one patients were on statin therapy.
On the whole, n= 37 patients required erythropoietin-stimulating agents, n= 35
received calcitriol, and n= 9 needed calcium carbonate phosphate binder therapy.
During follow-up, n= 49 CV events were recorded: n= 16 patients died from CV
causes (acute coronary syndrome n= 4, stroke n= 3, heart failure n= 8, and peripheral artery
disease n= 1), and there were n= 33 additional CV events (acute coronary syndrome n= 8,
stroke n= 6, heart failure n= 12, and peripheral artery disease n= 7).
Table II demonstrates the association of PWV, cSBP, cPP, and Aix (per one SD change
and per tertiles) with CV outcomes in models adjusted for age and sex or for traditional CV
risk factors. All the four studied parameters were significantly related to CV outcomes in
Fig. 1. Kaplan–Meier survival curves for each parameter studied with cardiovascular events (CV mortality and
CV events) as outcomes. Panel A: pulse wave velocity; Panel B: central systolic blood pressure; Panel C: central
pulse pressure; Panel D: augmentation index
ICPS risk score and categories for CV risk stratification 341
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Model 1. In the further adjusted Model 2, the association of PWV and cPP was attenuated to
non-significance, while cSBP and Aix showed significant associations. In the analyses of
tertiles, PWV and cPP showed a linear association with the risk of CV outcomes, while for
cSBP the association was non-linear: showing an increase only in the third tertile in Model 1
adjusted for age and sex. For Aix, no significant association was found, so this parameter was
omitted from the ICPS score calculation. Further adjustment for traditional CV risk factors in
Model 2 substantially attenuated the associations and none of them remained significant.
Unadjusted associations are shown as Kaplan–Meyer curves for each tertile of all four
parameters in Fig. 1.
Table III demonstrates hazard ratios for CV outcomes by ICPS risk scores and ICPS risk
categories. The risk categories were derived from Cox models (Table III) and Kaplan–Meier
(Fig. 2A) analyses by collapsing ICPS scores with similar hazard ratios and sufficient statistical
Table III. The relation of integrated central blood pressure–aortic stiffness (ICPS) risk score and ICPS risk categories
with cardiovascular morbidity and mortality based on Cox proportional hazard regression models
N Hazard ratio 95% CI p value
ICPS risk score
Model 1
0 18 1 (ref.)
1 17 1.831 0.339 9.876 0.482
2 16 1.528 0.233 10.018 0.659
3 24 5.719 1.298 25.208 0.021
4 13 4.236 0.849 21.131 0.078
5 12 11.105 2.366 52.120 0.002
ICPS risk categories
Model 1
Average 51 1 (ref.)
High 37 3.517 1.650 7.494 0.001
Very high 12 7.559 3.201 17.850 <0.001
Model 2
Average 51 1 (ref.)
High 37 4.583 1.867 11.253 0.001
Very high 12 8.563 3.086 23.758 <0.001
Diabetes 44 3.073 1.680 5.621 <0.001
Bold values demonstrate significance when p< 0.05. Model 1 is adjusted for age and sex. Model 2 is adjusted for age,
sex, brachial systolic blood pressure, LDL-cholesterol, current smoking, diabetes mellitus, body mass index,
cardiovascular disease, and GFR-EPI. ICPS: integrated central blood pressure–aortic stiffness; CI: confidence
interval
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power. Almost half of the patients were classified into the high- and very high-risk categories.
Kaplan–Meier survival curves for the three ICPS risk categories are shown in Fig. 2B.
Table III shows that the ICPS risk categories are strongly related to the CV outcomes
even after adjustment for traditional CV risk factors. It is also notable that in Model 2, ICPS
risk categories and diabetes were the only statistically significant predictors, with a higher risk
in the high and very high ICPS risk categories compared to diabetes.
Table IV demonstrates the results of the comparison of the discriminative ability of
the ICPS risk categories with the one SD change of PWV, cSBP, and cPP. All the parameters
Fig. 2. Kaplan–Meier survival curves for the integrated central blood pressure–aortic stiffness (ICPS) risk scores and
ICPS risk categories for cardiovascular events (CV mortality and CV events, adjusted for age and sex) as outcomes.
Panel A: ICPS risk score groups; Panel B: ICPS risk categories
Table IV. Comparison of the discriminative ability of the integrated central blood pressure–aortic stiffness risk
categories with the one standard deviation change of pulse wave velocity, central systolic blood pressure, and central
pulse pressure (Harrell’s C-statistics)
Variable Coefficient Standard error 95% CI p value
ICPS risk categories 0.723 0.036 0.652 0.795 <0.001
PWV 0.659 0.037 0.586 0.732 <0.001
cSBP 0.660 0.038 0.584 0.735 <0.001
cPP 0.691 0.035 0.621 0.761 <0.001
ICPS risk categories vs. PWV 0.065 0.029 0.007 0.122 0.028
ICPS risk categories vs. cSBP 0.064 0.024 0.017 0.110 0.008
ICPS risk categories vs. cPP 0.032 0.023 −0.014 0.079 0.170
Bold values demonstrate significance when p< 0.05. CI: confidence interval; ICPS risk categories: integrated central
blood pressure–aortic stiffness risk categories; PWV: carotid-femoral pulse wave velocity; cSBP: central systolic
blood pressure; cPP: central pulse pressure
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were adjusted for age and sex. ICPS risk categories were superior in the discrimination to PWV
and cSBP and a tendency was also present in case of cPP, but the difference was not significant.
When, as sensitivity analysis, all the calculations were repeated with the closure of
follow-up at the first event instead of multiple failure time analysis, similar results were found
(data are available from authors by request).
Discussion
This study demonstrated that the concept of an integrated score based on arterial stiffness and
central hemodynamic parameters (ICPS) is strongly related to incident CV events in CKD
patients. According to our results, people in high and very high ICPS risk categories are at a
remarkably high risk for CV events and have a risk that is stronger than that related to
diabetes, the strongest single predictor among traditional risk factors in our cohort. In
addition, it is better than PWV and cSBP and tends to be better than cPP, which suggests that
it is worth adding together the predictive power of these parameters.
A recent consensus statement suggests that the combined assessment of more than one
biomarker may improve CV outcome prediction (15). In line with this recommendation, this
study investigated the combined effect of arterial stiffness and central hemodynamic
parameters using a simple score that integrates the predictive information of individual
biomarkers.
Available studies have conflicting results regarding the role of non-invasive markers of
morphological or functional abnormalities of the arterial wall in relation to CV risk. In elderly
patients of the Rotterdam study, the evaluation of carotid intima-media thickness (c-IMT),
peripheral artery disease, or PWV marginally improved CV risk stratification over Framing-
ham risk factors (4, 14). In contrast, in middle-aged subjects from the atherosclerosis risk in
communities study, the detection of increased c-IMT and carotid artery plaques was
associated with a significant ∼23% net reclassification index (9).
There are also some data available about the joint evaluation of different non-invasive
hemodynamic biomarkers and their relation to CV outcomes. In the study of Wang et al. (16),
cSBP was superior in CV outcome prediction compared to brachial systolic blood pressure or
brachial or cPP. In the study of Holewijn et al. (3), using net reclassification improvement
analysis, CV risk stratification improved by adding non-invasive vascular risk markers, such
as PWV, Aix, or cSBP to traditional risk factors in women; however, the association was
weaker in men and was limited to men at intermediate risk. These results suggest that the joint
evaluation of different vascular biomarkers may have perspectives, but age and sex could
influence the results. Although we adjusted for age and sex throughout this study, ICPS risk
categories still remained robust predictors of CV events.
There are multiple potential advantages of the ICPS score concept. First, PWV, cSBP,
and cPP can easily be estimated with most of the available devices (e.g., tonometric,
mechanotransducer-based, or oscillometric) that measure arterial stiffness and use pulse
wave analysis. The ICPS score is determined in a non-invasive manner without blood
sampling, which is required for traditional risk scores. Furthermore, it could help to bridge
the huge problem of diverging methodologies. Thanks to creative engineers, newer and
newer devices are marketed that estimate these parameters in simpler ways, but the actual
results of these devices are not interchangeable. Our ICPS score based on tertiles in a given
population could be a universal parameter. Of course, the tertiles of each parameter should
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be defined for each device, but probably no equations are required to translate results
between devices. Although our studied three parameters correlate with each other, but our
results demonstrate, it is worth integrating them into one score as it can produce a very
strong predictor parameter.
As the ICPS score is based on a limited sample of CKD patients, we do not recommend
its calculation using the cutoff values from our sample, not even on CKD patients on
conservative therapy. A valid risk score should be based on large databases with a much
higher number of events that enable the investigation of each parameter involved in the score
(2). However, as our ICPS risk categories in the present rudimentary form are much stronger
predictors than diabetes in our cohort, our results in this form can generate important
discussion and further studies. A great scientific potential of this concept is related to the fact
that there are other cohorts in divergent races with available PWV, cSBP, and cPP
measurements, so our finding on ICPS risk categories could easily be broaden for different
patient populations. Such cohorts are, e.g., the Framingham Heart Study cohort (8) or the
Nijmegen Biomedical Study (3).
There are some limitations of this study that has to be acknowledged. During tonometric
arterial stiffness measurements, patients with atrial fibrillation are excluded because of
methodological considerations, so a proportion of patients cannot be involved into our new
risk stratification method. Due to the low number of participants and outcome events, this
study is underpowered and thus the exact thresholds for scoring or the relative contribution of
individual parameters could not have been exactly defined. Therefore, the aim of this study is
not to define the final score but to report the possible advantages of this new concept of a
combined risk score based on arterial stiffness and central hemodynamic parameters.
In conclusions, our integrated score and the constructed ICPS risk categories provided
strong and robust association with CV outcomes in CKD patients on conservative therapy,
which highlights the possible advantages of the combined measure of arterial stiffness and
central hemodynamic parameters for CV risk prediction.
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